Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine - MarketWatch

press release
March 29, 2010
Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine

HALIFAX, NOVA SCOTIA, Mar 29, 2010 -- Immunovaccine Inc. today announced that it has started screening patients for its Phase 1 clinical trial, investigating the company's therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is to establish the safety of the vaccine candidate which includes the DepoVax(TM) delivery platform. Secondary goals include an evaluation of dosing and an assessment of immune response.

"This study has significant implications for the company as it will determine the safety of the DPX-0907 vaccine in humans and contributes to our knowledge of the DepoVax(TM) platform," said Dr. Randal Chase, president and CEO of Immunovaccine. "A positive outcome from the Phase I study would be a catalyst for human therapeutic licensing deals for our DepoVax(TM) platform and allow us to move DPX-0907 further into the clinic."